These findings indicated that the increased levels of NSUN4 and ALYREF may function as promising clinical biomarkers for both HCC diagnosis and prognosis, and in-depth research concentrating on NSUN4- and ALYREF-mediated m5C modification may provide novel therapeutic targets and targeted intervention strategies for HCC treatment. Here, ALYREF is linked to hepatocellular carcinoma.